All In Biotech

Drug Trial Radar · NCT04157478

Addition of Anlotinib Hydrochloride to the Stupp Regimen Versus the Stupp Regimen Alone for Newly Diagnosed Glioblastoma

Addition of Anlotinib Hydrochloride to the Stupp Regimen Versus the Stupp Regimen Alone for Newly Diagnosed Glioblastoma: A Randomized Multicenter Prospective Phase II Study

Last checked: Nov 20, 2026Latest source record: Nov 12, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 464 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

464

Planned (sponsor's estimate)

Start

Jan 2020

Primary completion

Dec 2022

Study completion Dec 2024

Sponsor

Lead sponsor
People's Hospital of Guangxi Zhuang Autonomous RegionAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
First Affiliated Hospital of Guangxi Medical University; Cancer Hospital of Guangxi Medical University; Liuzhou Workers' Hospital; Nanxishan Hospital; LiuZhou People's Hospital; Affiliated Hospital of Guilin University
First posted
Nov 8, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

For patients with glioblastoma,postoperative radiotherapy combined with concurrent and adjuvant temozolomide (Stupp regimen) has long been considered a standard treatment approach.The treatment outcomes, however, are still dismal, with a median overall survival time of 8-12 months. As a novel small molecule multi-target tyrosine kinase inhibitor, anlotinib hydrochloride has been found to be able to inhibit both tumor angiogenesis and cell growth.Previous studies on recurrent glioblastoma have demonstrated its effectiveness in tumor control with manageable toxicities. The current study is designed to evaluate the efficacy and feasibility of the additional anlotinib hydrochloride to the Stupp regimen for newly diagnosed glioblastoma.

Conditions

  • Glioblastoma

Interventions

  • Anlotinib HydrochlorideDrug

    Anlotinib hydrochloride will be given with a daily dose of 12 mg for 14 days of a 21-day cycle up to 2 cycles, initiated on the first day of radiation therapy and followed by adjuvant treatment with the same dosing schedule until patients have disease progression or intolerable toxicities.

  • Radiation therapyRadiation

    Radiation therapy will be delivered in daily fractions of 2 Gy given 5 days a week for a total of 60 Gy.

  • TemozolomideDrug

    Temozolomide will be administered at a daily dose of 75 mg/m2 until the completion of radiation therapy. Four weeks after the completion of radiation therapy, patients will be given with adjuvant chemotherapy with temozolomide at a dose of 150-200 mg/m2 for 5 days of a 28-day cycle for a total of 6 cycles.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free survivalTime frame: 3 years

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • Nanxishan Hospital of Guangxi Zhuang Autonomous Region

    Guilin, Guangxi, China

  • Liuzhou Worker's Hospital

    Liuzhou, Guangxi, China

  • Liuzhou People's Hospital

    Liuzhou, Guangxi, China

  • Affiliated Hospital of Guangxi Medical University

    Nanning, Guangxi, China

  • Affiliated Tumor Hospital of Guangxi Medical University

    Nanning, Guangxi, China

  • People's Hospital of Guangxi Zhuang Autonomous Region

    Nanning, Guangxi, China

  • Yulin First Hospital

    Yulin, Guangxi, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.